Diversity of mechanism-based pharmacodynamic models.

Pharmacodynamics is the study of the time course of pharmacological effects of drugs. The field of pharmacodynamic modeling has made many advances, due in part to the relatively recent development of basic and extended mechanism-based models. The purpose of this article is to describe the classic as well as contemporary approaches, with an emphasis on pertinent equations and salient model features. In addition, current methods of integrating various system complexities into these models are discussed. Future pharmacodynamic models will most likely reflect an assembly of the basic components outlined in this review.

[1]  W J Jusko,et al.  Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena. , 1998, Journal of pharmaceutical sciences.

[2]  J. Wagner,et al.  Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man. , 1968, Journal of theoretical biology.

[3]  Wojciech Krzyzanski,et al.  Mathematical Modeling of Circadian Cortisol Concentrations Using Indirect Response Models: Comparison of Several Methods , 1999, Journal of Pharmacokinetics and Biopharmaceutics.

[4]  G. Levy,et al.  RELATIONSHIP BETWEEN ELIMINATION RATE OF DRUGS AND RATE OF DECLINE OF THEIR PHARMACOLOGIC EFFECTS. , 1964, Journal of pharmaceutical sciences.

[5]  L B Sheiner,et al.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. , 1980, Clinical pharmacology and therapeutics.

[6]  R. Ramakrishnan,et al.  Fifth-Generation Model for Corticosteroid Pharmacodynamics: Application to Steady-State Receptor Down-Regulation and Enzyme Induction Patterns During Seven-Day Continuous Infusion of Methylprednisolone in Rats , 2002, Journal of Pharmacokinetics and Pharmacodynamics.

[7]  Terrence P. Kenakin,et al.  A Pharmacologic Analysis of Drug-Receptor Interaction , 1987 .

[8]  L B Sheiner,et al.  Kinetics of pharmacologic response. , 1982, Pharmacology & therapeutics.

[9]  W. Jusko,et al.  Gender‐based effects on methylprednisolone pharmacokinetics and pharmacodynamics , 1993, Clinical pharmacology and therapeutics.

[10]  R. Furchgott,et al.  The pharmacology of vascular smooth muscle. , 1955, Pharmacological reviews.

[11]  W J Jusko,et al.  Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. , 1998, Journal of pharmaceutical sciences.

[12]  G Levy,et al.  Pharmacologic target‐mediated drug disposition , 1994, Clinical pharmacology and therapeutics.

[13]  T Iga,et al.  Comparative pharmacodynamics of eight calcium channel blocking agents in Japanese essential hypertensive patients. , 1996, Biological & pharmaceutical bulletin.

[14]  W J Jusko,et al.  Physiologic indirect response models characterize diverse types of pharmacodynamic effects , 1994, Clinical pharmacology and therapeutics.

[15]  M Danhof,et al.  Mechanism-based pharmacokinetic-pharmacodynamic modeling of antilipolytic effects of adenosine A(1) receptor agonists in rats: prediction of tissue-dependent efficacy in vivo. , 1999, The Journal of pharmacology and experimental therapeutics.

[16]  G. Levy,et al.  Kinetics of pharmacologic effects in man: The anticoagulant action of warfarin , 1969, Clinical pharmacology and therapeutics.

[17]  W J Jusko,et al.  Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents. , 1971, Journal of pharmaceutical sciences.

[18]  Peter C Preusch.  What IS training in the Pharmacological Sciences? , 2002, Molecular interventions.

[19]  William J. Jusko,et al.  A pharmacodynamic model for cell-cycle-specific chemotherapeutic agents , 1973, Journal of Pharmacokinetics and Biopharmaceutics.

[20]  M Danhof,et al.  Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of the Electroencephalogram Effects of GABAA Receptor Modulators: In Vitro-in Vivo Correlations , 2003, Journal of Pharmacology and Experimental Therapeutics.

[21]  Wojciech Krzyzanski,et al.  Indirect Pharmacodynamic Models for Responses with Multicompartmental Distribution or Polyexponential Disposition , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[22]  Ariens Ej,et al.  Affinity and intrinsic activity in the theory of competitive inhibition. I. Problems and theory. , 1954 .

[23]  Kenji Chiba,et al.  Pharmacokinetics and cell trafficking dynamics of 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride (FTY720) in cynomolgus monkeys after single oral and intravenous doses. , 2002, The Journal of pharmacology and experimental therapeutics.

[24]  John Anthony Bauer,et al.  Pharmacodynamic Models of Nitroglycerin-Induced Hemodynamic Tolerance in Experimental Heart Failure , 1994, Pharmaceutical Research.

[25]  G Levy,et al.  Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. , 1992, Journal of clinical pharmacology.

[26]  K. Netter,et al.  Pharmacologic analysis of drug-receptor interaction , 1994 .

[27]  G Levy,et al.  Kinetics of pharmacologic effects , 1966, Clinical pharmacology and therapeutics.

[28]  E. J. Ariëns.  Molecular pharmacolōgy : the mode of action of biologically active compounds , 1964 .

[29]  Donald E. Mager,et al.  General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[30]  Y. Yano,et al.  Application of logistic growth model to pharmacodynamic analysis of in vitro bactericidal kinetics. , 1998, Journal of pharmaceutical sciences.

[31]  P H van der Graaf,et al.  A set-point model with oscillatory behavior predicts the time course of 8-OH-DPAT-induced hypothermia. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.

[32]  Jianguo Zhi,et al.  Microbial pharmacodynamics of piperacillin in neutropenic mice of systematic infection due toPseudomonas aeruginosa , 1988, Journal of Pharmacokinetics and Biopharmaceutics.

[33]  Wojciech Krzyzanski,et al.  Mathematical Formalism and Characteristics of Four Basic Models of Indirect Pharmacodynamic Responses for Drug Infusions , 2004, Journal of Pharmacokinetics and Biopharmaceutics.

[34]  U. Bhalla,et al.  Emergent properties of networks of biological signaling pathways. , 1999, Science.

[35]  M O Karlsson,et al.  A model for the turnover of dihydrotestosterone in the presence of the irreversible 5α‐reductase inhibitors GI198745 and finasteride , 1998, Clinical pharmacology and therapeutics.

[36]  J. Foreman,et al.  Textbook of Receptor Pharmacology , 2011 .

[37]  H E Wichmann,et al.  A mathematical model of erythropoiesis in mice and rats. Part 4: Differences between bone marrow and spleen , 1990, Cell and tissue kinetics.

[38]  G Levy,et al.  Mechanism‐based pharmacodynamic modeling , 1994, Clinical pharmacology and therapeutics.

[39]  Yasuhiko Yamada,et al.  Parmacodynamic Analysis of Antiplatelet Effect of Aspirin in the Literature. Modeling Based on Inhibition of Cyclooxygenase in the Platelet and the Vessel Wall Endothelium. , 1996 .

[40]  P Gozzi,et al.  Pharmacokinetic-pharmacodynamic modeling of the immunomodulating agent susalimod and experimentally induced tumor necrosis factor-alpha levels in the mouse. , 1999, The Journal of pharmacology and experimental therapeutics.

[41]  Mats O. Karlsson,et al.  Interchangeability and Predictive Performance of Empirical Tolerance Models , 1999, Clinical pharmacokinetics.

[42]  W J Jusko,et al.  Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys. , 2000, The Journal of pharmacology and experimental therapeutics.

[43]  M O Karlsson,et al.  A turnover model of irreversible inhibition of gastric acid secretion by omeprazole in the dog. , 2000, The Journal of pharmacology and experimental therapeutics.

[44]  Donald E. Mager,et al.  Receptor-Mediated Pharmacokinetic/Pharmacodynamic Model of Interferon-β 1a in Humans , 2002, Pharmaceutical Research.

[45]  W J Jusko,et al.  Pharmacodynamic modeling of time‐dependent transduction systems , 2001, Clinical pharmacology and therapeutics.

[46]  T Iga,et al.  Pharmacokinetic and pharmacodynamic study of a new nonsteroidal 5 alpha-reductase inhibitor, 4-[3-[3-[Bis(4-isobutylphenyl)methylamino]benzoyl]-1H-indol-1-yl]-butyr ic acid, in rats. , 1998, The Journal of pharmacology and experimental therapeutics.

[47]  Wojciech Krzyzanski,et al.  A signal transduction pharmacodynamic model of the kinetics of the parasympathomimetic activity of low-dose scopolamine and atropine in rats. , 2002, Journal of pharmaceutical sciences.

[48]  M. Hammarlund-Udenaes,et al.  Prolactin release after remoxipride by an integrated pharmacokinetic-pharmacodynamic model with intra- and interindividual aspects. , 1995, The Journal of pharmacology and experimental therapeutics.

[49]  N. Saijo,et al.  Indirect‐response model for the time course of leukopenia with anticancer drugs , 1998, Clinical pharmacology and therapeutics.

[50]  W J Jusko,et al.  Prednisolone Pharmacokinetics and Pharmacodynamics in Relation to Sex and Race , 2001, Journal of clinical pharmacology.

[51]  Adriaan Cleton,et al.  Application of a Combined “Effect Compartment/Indirect Response Model” to the Central Nervous System Effects of Tiagabine in the Rat , 1999, Journal of Pharmacokinetics and Biopharmaceutics.

[52]  A. Vinks,et al.  Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion , 1997, Antimicrobial agents and chemotherapy.

[53]  R. Ramakrishnan,et al.  Basic Pharmacodynamic Models for Agents That Alter Production of Natural Cells , 1999, Journal of Pharmacokinetics and Biopharmaceutics.

[54]  J. Black,et al.  Operational models of pharmacological agonism , 1983, Proceedings of the Royal Society of London. Series B. Biological Sciences.

[55]  Varun Garg,et al.  Comparison of four basic models of indirect pharmacodynamic responses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.